4 Healthcare Stock Stories Prescribed for Investors

Teva Pharmaceutical Industries Limited (NYSE:TEVA): Current price $38.83

The Israel-based generic-drug maker Teva might be liable for $2.1 billion in damages because of its selling generic copies of Pfizer’s heartburn reliever Protonix prior to the medication’s United States patent exclusivity expiring back in 2011. The firm had already set a $670 million reserve aside in the third quarter in case of a Protonix loss, but now in its 2012 annual report filed Tuesday with the Securities and Exchange Commission, it was disclosed that its management estimates the ultimate resolution of this matter could result in a loss of up to $1.4 billion more.